INTELLIGENT BIO SOLUTIONS INC
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
INBS$2.25-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
FINANCIAL INFORMATION Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets
| As of March 31, | As of June 30, | |
|---|---|---|
| 2024 | 2023 | |
| (Unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $9,397,523 | $1,537,244 |
| Accounts receivable, net | 431,646 | 293,861 |
| Inventories, net | 877,905 | 979,907 |
| Research and development tax incentive receivable | 332,471 | 498,758 |
| Other current assets | 481,046 | 552,791 |
| Total current assets | 11,520,591 | 3,862,561 |
| Property and equipment, net | 559,520 | 690,175 |
| Operating lease right-of-use assets | 365,512 | 546,475 |
| Intangibles, net | 4,593,330 | 5,255,401 |
| Total assets | $17,038,953 | $10,354,612 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $2,128,747 | $2,610,028 |
| Current portion of operating lease liabilities | 260,377 | 223,447 |
| Current portion of deferred grant income | 2,288,660 | 2,338,057 |
| Current employee benefit liabilities | 660,010 | 358,942 |
| Current portion of notes payable | 368,513 | 353,211 |
| Total current liabilities | 5,706,307 | 5,883,685 |
| Employee benefit liabilities, less current portion | 30,286 | 24,902 |
| Operating lease liabilities, less current portion | 154,162 | 356,165 |
| Notes payable, less current portion | 150,426 | 402,862 |
| Total liabilities | 6,041,181 | 6,667,614 |
| Commitments and contingencies (Note 13) | - | - |
| Shareholders’ equity | ||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 2,913,799 and 194,200 shares issued and outstanding at March 31, 2024 and June 30, 2023, respectively* | 29,135 | 1,942 |
| Treasury stock, at cost, 116 shares as of March 31, 2024 and June 30, 2023, respectively* | (1) | (1) |
| Additional paid-in capital | 60,946,174 | 46,180,112 |
| Accumulated deficit | (49,180,085) | (41,807,573) |
| Accumulated other comprehensive loss | (662,405) | (575,496) |
| Total consolidated Intelligent Bio Solutions Inc. equity | 11,132,818 | 3,798,984 |
| Non-controlling interest | (135,046) | (111,986) |
| Total shareholders’ equity | 10,997,772 | 3,686,998 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $17,038,953 | $10,354,612 |
| * | Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.